普乐可复在肝脏移植术后的免疫治疗与监测

目的：观察肝脏移植术后应用普乐可复（FK506）免疫治疗的临床效果。方法：回顾性分析我院69例患者肝脏移植术后使用以FK506为基础的三联免疫治疗方案的临床资料，即FK506＋霉酚酸酯（MMF）＋皮质激素。结果：69例中发生急性排斥反应8例（11．6％），经调整药物剂量后逆转。FK506的副作用主要有精神及神经系统紊乱（20．3％）、高血压（11．6％）、血糖升高（20．3％）及肝肾功能异常（8.7％）等。结论：FK506是一种安全、强效的免疫抑制药物，用药剂量应根据药物谷值浓度及个体差异进行调整。

Immunotherapeutic and monitoring of tacrolimus in recipients of liver transplantation

Objective:To observe the clinic therapeutic effects of tacrolimus(FK506) in the recipients who had undergone liver transplantation.Methods:The clinical data of 69 recipients of allogeneic liver transplantation followed by tacrolimus based immunotherapeutic scheme were retrospectively analyzed in our hospital.After liver transplantation, all the recipients received the trilogy-drug immunosuppressive protocol, including tacrolimus(FK506) as the basic drug, mycophenolat-mofetil(MMF), and prednisone.Results:Acute rejection occurred in 8 of 69 cases(11.6%).After adjusting drug dose, acute rejection was reversed.The main side-effects of tacrolimus were spirit and nervous system confusion (20.3%), hypertension(11.6%), hyperglycemia(20.3%), liver and renal dysfunction(8.7%).Conclusion:Tacrolimus is a safe and potent immunosuppressive medicine, the dosage of FK506 should be adjusted according to trough level within the therapeutic window and individualized.